Sort   by:  
 Page size 
TranscriptomicsGene expression changes in subclones of a Burkitt lymphoma cell line with different patterns of EBV latent infection
In this study we have investigated the gene expression profiles of three different types of subclone all generated by single cell cloning of the same parental EBV positive Burkitt lymphoma cell line Awia-BL. These included EBV negative clones which have lost the virus episome, EBV positive clones w...
ORGANISM(S): Homo sapiens 
2013-01-22 | E-GEOD-42867 | biostudies-arrayexpress
UnknownSystematic genomic and translational efficiency studies of uveal melanoma.
Not available
S-EPMC5464544 | biostudies-literature
UnknownAssessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Not available
S-EPMC8990358 | biostudies-literature
UnknownReprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Not available
S-EPMC8369408 | biostudies-literature
UnknownAnti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Not available
S-EPMC11581602 | biostudies-literature
UnknownEfficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Not available
S-EPMC8563380 | biostudies-literature
UnknownAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213 | biostudies-literature
Genomicsena-DATASET-MDACC-02-02-2018-10:54:47:473-560 - samples
The oral and gut microbiomes of melanoma patients were characterized before the initiation of ant-PD1 immunotherapy, and compared to treatment response. Validation studies were performed in germ-free mice using stool from patients who responded/did not respond to ant-PD1 immunotherapy. All baseline...
EGAD00001003943 | EGA
UnknownShort-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.
Not available
S-EPMC8583008 | biostudies-literature
GenomicsThis committee is composed on individuals who have access to the data corresponding to this project: Gut microbiome modulates response to anti PD-1 immunotherapy in melanoma patients
Data Access Committee EGAC00001000758
EGAC00001000758 | EGA
Sort   by:  
 Page size